首頁 > 市場調查報告書 > 製藥

個人化醫學

市場調查報告書

商品編碼

2126413

伴隨診斷（CDx）市場－監理情勢分析，2026年

Companion Diagnostics (CDx) Market - Regulatory Landscape Analysis, 2026

出版日期: 2026年08月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

伴隨診斷的監管格局正在經歷重大變革，其驅動力包括精準醫療模式轉移、基於生物標記的療法研發日益複雜化，以及伴隨診斷與臨床開發和法規核准流程的日益融合。這一市場演變的特點在於，人們逐漸檢驗到伴隨診斷對於確定特定治療產品的適用性以及將已驗證的生物標記與標靶治療聯繫起來至關重要，尤其是在腫瘤領域，分子異質性會顯著影響治療反應。次世代定序、聚合酵素鏈鎖反應(PCR) 和免疫組織化學等先進分子技術的融合，使得生物標記的評估更加全面和標準化。監管機構正在製定核准流程，以促進對治療和診斷產品的協調審查，同時又不降低分析和臨床檢驗標準。製藥公司正在藥物研發的早期階段引入伴隨診斷，以簡化臨床試驗的招募流程、提高反應率並加強支持法規核准的臨床證據。隨著對市場中檢驗的測試平台、品管系統和上市後調查計畫的大量投資，伴隨診斷正在成為全球醫療保健系統中實現精準醫療的關鍵要素。

市場促進因素

生物標記主導的藥物研發的擴展是伴隨診斷監管格局的主要驅動力。精準腫瘤學越來越依賴生物標記定義的患者群體，因為標靶治療在應用於具有特定分子突變的患者時才能帶來最大的臨床效益。隨著製藥公司研發管線涵蓋EGFR、HER2、ALK、ROS1、BRAF、KRAS、BRCA、RET、MET、NTRK和FGFR等生物標記，檢驗的伴隨診斷不再只是可有可無的商業化工具，而是臨床開發的關鍵組成部分。隨著針對罕見基因組突變的在臨床實驗藥物不斷增加，申辦者需要高靈敏度的檢測方法，以便在多種醫療機構中識別合格的患者。由於基於生物標記的受試者選擇能夠提高反應率並降低患者異質性，伴隨診斷擴大從試驗設計的早期階段就被納入臨床開發。這種方法降低了後期臨床試驗失敗的可能性，並增強了支持監管申報的證據，從而推動了伴隨診斷應用的持續成長。治療和診斷試劑共同開發的監管協調正透過統一的審查流程進一步加速市場成長。監管機構日益認知到治療效果和診斷準確性之間的相互依存關係，因為生物標記的錯誤識別會直接影響治療結果。美國FDA持續推動治療試劑和伴隨診斷試劑的共同審查，其他監管機構也正在製定類似的框架，以提高審查效率，同時不降低證據標準。越來越多的申辦者在臨床實驗早期階段就開始與監管機構進行磋商，因為同步規劃可以減少治療試劑和診斷試劑證據包之間的差異。次世代定序正在改變綜合生物標記檢測，它能夠同時檢測可用於多種療法的基因組變異。隨著癌症治療越來越依賴多種基因組變異的同步評估，全面的基因組分析正成為一種首選的診斷策略。

市場限制因素

全球各地的監管證據要件各不相同，導致研發成本增加、核准時間延長，以及伴隨診斷產品同步商業化策略複雜。區域差異為全球研發項目帶來挑戰。先進分子檢測的保險報銷缺乏一致性，限制了其在臨床常規應用，尤其是在基因組檢測資金來源具有選擇性或依賴醫療機構的醫療體系中。保險覆蓋範圍的區域差異給診斷服務提供者帶來不確定性，並限制了患者的就醫途徑。生物標記檢測基礎設施、檢查室專業技術和檢測標準化方面的差異阻礙了患者公平地獲得檢測，並造成診斷性能的區域差異。缺乏統一的基礎設施給一致部署帶來了挑戰。不同司法管轄區的監管複雜性給尋求商業化新型診斷解決方案的製造商帶來了合規負擔。

市場定義和範圍
伴隨診斷（CDx）產業概覽
全球伴隨診斷法規的變化
主要市場趨勢
市場規模表現分析
市場預測
伴隨診斷在精準醫療中的監管作用
伴隨診斷開發及與製藥公司合作開發的框架
按治療領域分類的伴隨診斷核准趨勢
伴隨診斷開發生命週期

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

伴隨診斷領域的新興技術
產品創新
臨床試驗分析
管道分析
生物標記發現與檢驗的趨勢
將次世代定序(NGS) 整合到伴隨診斷 (CDx) 開發中
人工智慧與數位病理學的融合

第7章監理情勢

全球伴隨診斷法律規範
法規核准流程
合規要求
美國法律規範（FDA）
歐洲法規結構（與體外診斷醫療器材法規和歐洲藥品管理局協調）
日本的法律規範（PMDA 和厚生勞動省）
中國的法規結構（NMPA）
韓國的法律規範（MFDS）
加拿大法律規範（加拿大衛生署）
澳洲法律規範（TGA）
為實現監管協調所做的努力
伴隨診斷和治療藥物同時核准的要求
標籤要求以及藥品和診斷試劑之間的相互依存關係
檢查室自建檢測方法（LDT）及監管考量
上市後監測與生命週期監管管理

第8章：伴隨診斷（CDx）的監管分析

分析：按技術平台
分析：依生物標記類型
分析：依樣本類型
分析：按測試方法
分析：按治療領域
分析：透過監管流程
分析：按最終用戶

第9章：伴隨診斷（CDx）監理現況的細分分析

透過技術平台
- 聚合酵素鏈鎖反應（PCR）
- 次世代定序（NGS）
- 免疫組織化學（IHC）
- 原位雜合反應（ISH）
- 其他
依生物標誌類型
- 基因生物標記
- 蛋白質體學生物標記
- 轉錄組生物標記
- 其他
依樣本類型
- 組織切片檢查
- 液態生物檢體
- 唾液
- 其他生物檢體
按治療區域
- 腫瘤學
- 血液學
- 神經病學
- 感染疾病
- 自體免疫疾病
- 罕見疾病
- 其他
透過監管程序
- 新伴隨診斷的批准
- 治療藥物和伴隨診斷試劑的共同開發和同步核准
- 適應性擴展和生命週期管理
- 快速核准和特殊核准的監理途徑
- 其他
最終用戶
- 製藥和生物技術公司
- 體外診斷試劑生產商
- 臨床實驗室
- 其他

第10章：伴隨診斷（CDx）監管狀況的區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：各國伴隨診斷（CDx）法規分析

美國
加拿大
德國
法國
英國
義大利
西班牙
日本
中國
韓國
澳洲
印度
巴西
沙烏地阿拉伯

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd.
Agilent Technologies, Inc.
QIAGEN NV
Thermo Fisher Scientific Inc.
Illumina, Inc.
BioMerieux
Exact Sciences
Guardant Health, Inc.
Foundation Medicine, Inc.
Abbott Laboratories

第14章：伴隨診斷（CDx）的監理現況及市場預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009124

The companion diagnostics regulatory landscape is undergoing significant transformation driven by the paradigm shift toward precision medicine, the increasing complexity of biomarker-guided therapeutic development, and the growing integration of companion diagnostics into clinical development and regulatory approval pathways. The market's evolution is characterized by the recognition that companion diagnostics are essential for determining patient eligibility for specific therapeutic products, linking validated biomarkers with targeted treatments, particularly in oncology where molecular heterogeneity significantly influences therapeutic response. The convergence of advanced molecular technologies, including next-generation sequencing, polymerase chain reaction, and immunohistochemistry, is enabling more comprehensive and standardized biomarker assessment. Regulatory authorities are refining approval pathways that encourage coordinated review of therapeutics and diagnostics without compromising analytical and clinical validation standards. Pharmaceutical companies are integrating companion diagnostics earlier in drug development to improve trial enrollment efficiency, increase response rates, and strengthen clinical evidence supporting regulatory approval. The market is witnessing significant investment in validated testing platforms, quality management systems, and post-market surveillance programs, positioning companion diagnostics as a critical enabler of precision medicine across global healthcare systems.

Market Drivers

The expansion of biomarker-driven drug development represents the primary driver for the companion diagnostics regulatory landscape. Precision oncology increasingly depends on biomarker-defined patient populations because targeted therapies demonstrate the greatest clinical benefit when administered to patients with specific molecular alterations. Pharmaceutical pipelines are continuing to expand across biomarkers such as EGFR, HER2, ALK, ROS1, BRAF, KRAS, BRCA, RET, MET, NTRK, and FGFR, making validated companion diagnostics an essential component of clinical development rather than an optional commercialization tool. As more investigational drugs target rare genomic alterations, sponsors require highly sensitive assays capable of identifying eligible patients across multiple healthcare settings. Clinical development is increasingly incorporating companion diagnostics during early trial design because biomarker-guided enrollment improves response rates while reducing patient heterogeneity. This approach lowers the probability of late-stage clinical failure and strengthens evidence supporting regulatory submissions, resulting in sustained growth in companion diagnostic utilization. Regulatory alignment for therapeutic-diagnostic co-development is further accelerating market growth through coordinated review pathways. Regulatory agencies increasingly recognize that therapeutic effectiveness and diagnostic accuracy are interdependent because incorrect biomarker identification directly affects treatment outcomes. The U.S. FDA continues to promote coordinated review of therapeutic products and companion diagnostics, while other regulatory authorities are refining similar frameworks to improve review efficiency without reducing evidentiary standards. Sponsors are increasingly initiating regulatory engagement during early clinical development because simultaneous planning reduces discrepancies between therapeutic and diagnostic evidence packages. Next-generation sequencing is transforming comprehensive biomarker testing by enabling simultaneous detection of multiple actionable genomic alterations. Comprehensive genomic profiling is becoming a preferred diagnostic strategy because oncology treatments increasingly depend on simultaneous assessment of multiple genomic alterations.

Market Restraints

Regulatory evidence requirements differ across global jurisdictions, increasing development costs, extending approval timelines, and complicating simultaneous commercialization strategies for companion diagnostics. Differences across regions create challenges for global development programs. Limited reimbursement consistency for advanced molecular testing restricts routine clinical adoption, particularly in healthcare systems where genomic testing remains selectively funded or institution-dependent. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Variability in biomarker testing infrastructure, laboratory expertise, and assay standardization reduces equitable patient access and creates differences in diagnostic performance across geographic regions. The lack of harmonized infrastructure creates challenges for consistent implementation. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Product Insights

The technology landscape is characterized by the growing importance of comprehensive genomic profiling, liquid biopsy, and integrated bioinformatics platforms. NGS represents the fastest-evolving technology platform because precision oncology increasingly depends on simultaneous detection of multiple clinically actionable biomarkers. Drug developers are incorporating NGS into clinical trials to improve enrollment efficiency while reducing sequential testing requirements. This shift increases demand for comprehensive genomic profiling capable of supporting numerous targeted therapies using a single tissue or liquid biopsy sample. Diagnostic manufacturers continue expanding panel content, automation capabilities, and bioinformatics solutions because laboratories require scalable workflows that maintain analytical accuracy. PCR remains important for focused mutation detection where rapid turnaround is prioritized. IHC continues supporting protein biomarker assessment. ISH remains essential for gene amplification and rearrangement detection. Liquid biopsy is expanding companion diagnostic applications beyond initial diagnosis through minimally invasive blood samples. The segment analysis reveals that concurrent therapeutic and companion diagnostic development is becoming the preferred regulatory strategy because synchronized evidence generation reduces commercialization delays while strengthening regulatory confidence. Pharmaceutical sponsors are integrating diagnostic partners during early clinical development to ensure analytical validation progresses alongside pivotal therapeutic studies. Oncology represents the dominant therapeutic area because genomic alterations increasingly determine treatment eligibility across solid tumors and hematologic malignancies. Pharmaceutical and biotechnology companies represent the primary end-user segment because targeted therapeutics increasingly require validated companion diagnostics before commercialization. The integration of AI is becoming increasingly important because AI supports automated image analysis, genomic variant interpretation, and biomarker prioritization across multiple diagnostic platforms.

Competitive and Strategic Outlook

The competitive landscape features established diagnostics and life science companies alongside specialized precision oncology, molecular, and liquid biopsy providers. Roche maintains one of the strongest strategic positions because it combines pharmaceutical development with one of the industry's largest in vitro diagnostics businesses, enabling alignment of biomarker discovery, assay development, clinical validation, and regulatory submissions throughout the therapeutic lifecycle. Agilent Technologies differentiates itself through its expertise in pathology diagnostics, molecular biology, and laboratory workflow solutions supporting biomarker-guided oncology development, continuing to strengthen its companion diagnostic capabilities through the Dako pathology portfolio, automated staining platforms, and validated IHC assays. QIAGEN has established a strong position by combining molecular testing technologies with extensive pharmaceutical partnerships supporting targeted therapy development, continuing to expand its therascreen companion diagnostic portfolio across multiple oncology biomarkers using PCR and NGS technologies. Thermo Fisher Scientific occupies a significant position through its comprehensive molecular diagnostics portfolio, global laboratory infrastructure, and extensive pharmaceutical collaborations, with its Oncomine NGS platform supporting comprehensive genomic profiling. Illumina remains a technology leader because its sequencing platforms form the foundation of comprehensive genomic profiling across clinical research and commercial molecular testing laboratories worldwide. Guardant Health has differentiated itself by advancing liquid biopsy technologies that complement conventional tissue-based companion diagnostics. Companies are pursuing product portfolio expansion through innovation in NGS panels, liquid biopsy assays, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside targeted therapies. Recent key developments include Foundation Medicine announcing that the U.S. FDA approved FoundationOne CDx and FoundationOne Liquid CDx to identify BRCA1/2-mutated metastatic castration-resistant prostate cancer patients eligible for Lynparza plus abiraterone and steroid therapy, extending the company's tissue- and blood-based CDx labels for a broader prostate cancer treatment setting. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The companion diagnostics regulatory landscape is positioned for sustained growth driven by the convergence of biomarker-driven drug development, regulatory co-development, and technological innovation. The transition from supporting individual therapies toward becoming foundational infrastructure for precision healthcare represents a fundamental shift in precision medicine. While challenges related to regulatory variability, reimbursement inconsistency, and infrastructure limitations persist, strategic investments in technology, partnerships, and regulatory expertise are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with companion diagnostics evolving into an essential component of precision healthcare, supporting therapeutic development, patient selection, and improved clinical outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Companion Diagnostics (CDx) Regulatory Landscape Analysis Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Companion Diagnostics (CDx) Industry Overview
3.3 Evolution of the Global Companion Diagnostics Regulatory Landscape
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Regulatory Role of Companion Diagnostics in Precision Medicine
3.8 Companion Diagnostic Development & Drug Co-Development Framework
3.9 Companion Diagnostic Approval Trends by Therapeutic Area
3.10 Companion Diagnostic Development Lifecycle

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies in Companion Diagnostics
6.2 Product Innovation
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 Biomarker Discovery & Validation Trends
6.6 Next-Generation Sequencing (NGS) Integration in CDx Development
6.7 Artificial Intelligence & Digital Pathology Integration

7. Regulatory Landscape

7.1 Global Regulatory Framework for Companion Diagnostics
7.2 Regulatory Approval Pathways
7.3 Compliance Requirements
7.4 United States Regulatory Framework (FDA)
7.5 European Regulatory Framework (IVDR & EMA Collaboration)
7.6 Japan Regulatory Framework (PMDA & MHLW)
7.7 China Regulatory Framework (NMPA)
7.8 South Korea Regulatory Framework (MFDS)
7.9 Canada Regulatory Framework (Health Canada)
7.10 Australia Regulatory Framework (TGA)
7.11 Regulatory Harmonization Initiatives
7.12 Companion Diagnostic-Therapeutic Co-Approval Requirements
7.13 Labeling Requirements & Drug-Diagnostic Interdependency
7.14 Laboratory Developed Tests (LDTs) and Regulatory Considerations
7.15 Post-Market Surveillance & Lifecycle Regulatory Management

8. Companion Diagnostics (CDx) Regulatory Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Biomarker Type
8.3 Analysis by Sample Type
8.4 Analysis by Testing Methodology
8.5 Analysis by Therapeutic Area
8.6 Analysis by Regulatory Pathway
8.7 Analysis by End User

9. Companion Diagnostics (CDx) Regulatory Landscape Segment Analysis (2021-2035)

9.1 By Technology Platform
- 9.1.1 Polymerase Chain Reaction (PCR)
- 9.1.2 Next-Generation Sequencing (NGS)
- 9.1.3 Immunohistochemistry (IHC)
- 9.1.4 In Situ Hybridization (ISH)
- 9.1.5 Others
9.2 By Biomarker Type
- 9.2.1 Genomic Biomarkers
- 9.2.2 Proteomic Biomarkers
- 9.2.3 Transcriptomic Biomarkers
- 9.2.4 Others
9.3 By Sample Type
- 9.3.1 Tissue Biopsy
- 9.3.2 Liquid Biopsy
- 9.3.3 Saliva
- 9.3.4 Other Biological Samples
9.4 By Therapeutic Area
- 9.4.1 Oncology
- 9.4.2 Hematology
- 9.4.3 Neurology
- 9.4.4 Infectious Diseases
- 9.4.5 Autoimmune Diseases
- 9.4.6 Rare Diseases
- 9.4.7 Others
9.5 By Regulatory Pathway
- 9.5.1 New Companion Diagnostic Approval
- 9.5.2 Therapeutic-CDx Co-development & Concurrent Approval
- 9.5.3 Label Expansion & Lifecycle Management
- 9.5.4 Accelerated & Special Regulatory Pathways
- 9.5.5 Others
9.6 By End User
- 9.6.1 Pharmaceutical & Biotechnology Companies
- 9.6.2 In Vitro Diagnostic Manufacturers
- 9.6.3 Clinical Laboratories
- 9.6.4 Others

10. Companion Diagnostics (CDx) Regulatory Landscape Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Companion Diagnostics (CDx) Regulatory Landscape Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 France
11.5 United Kingdom
11.6 Italy
11.7 Spain
11.8 Japan
11.9 China
11.10 South Korea
11.11 Australia
11.12 India
11.13 Brazil
11.14 Saudi Arabia

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 F. Hoffmann-La Roche Ltd.
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Agilent Technologies, Inc.
13.3 QIAGEN N.V.
13.4 Thermo Fisher Scientific Inc.
13.5 Illumina, Inc.
13.6 BioMerieux
13.7 Exact Sciences
13.8 Guardant Health, Inc.
13.9 Foundation Medicine, Inc.
13.10 Abbott Laboratories